Alterity Therapeutics Limited Share Price
Stocks
ATH
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
10:40:12 13/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.2500 AUD | 0.00% |
|
-5.66% | -37.50% |
| 05/10 | Alterity Therapeutics Limited Presents New Analyses of Ath434 Phase 2 Data in Multiple System Atrophy | CI |
| 16/09 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| Market Cap | 3.88Cr 3.52Cr 3.25Cr 2.94Cr 5.53Cr 366.03Cr 5.73Cr 39Cr 15Cr 195.52Cr 15Cr 14Cr 620.65Cr | P/E 2027 * |
-2.44x | P/E 2028 * | -0.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.89Cr 2.62Cr 2.42Cr 2.18Cr 4.11Cr 272.18Cr 4.26Cr 29Cr 12Cr 145.39Cr 11Cr 11Cr 461.52Cr | EV / Sales 2027 * |
22.8x | EV / Sales 2028 * | 0.83x |
| Free-Float |
96.2% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| ATH | Delayed | |
OTC Markets
| PRNAF | Delayed | |
|
Deutsche Boerse AG
| PBN | Delayed | |
|
Börse Stuttgart
| PBN | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 week | -5.66% | ||
| Current month | -5.66% | ||
| 1 month | -26.47% | ||
| 3 months | -53.27% | ||
| 6 months | -50.00% | ||
| Current year | -37.50% |
| 1 week | 0.24 |  | 0.3 |
| 1 month | 0.23 | | 0.32 |
| Current year | 0.23 | | 0.78 |
| 1 year | 0.23 | | 0.78 |
| 3 years | 0.1 | | 0.95 |
| 5 years | 0.1 | | 1.45 |
| 10 years | 0.1 | | 20.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Exercice | Director | 47,620 | 0.0216% | ||
| 31/08/26 | Buy | Chief Executive Officer | -47,620 | 0.0216% | ||
| 31/08/26 | Buy | Director | 95,240 | 0.0432% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -5.66% | -44.44% | -16.67% | 3.88Cr | |
| -2.69% | -0.48% | +51.67% | +69.09% | 6.63TCr | |
| -0.92% | +7.67% | +14.26% | +90.92% | 6.06TCr | |
| 0.00% | +0.39% | +20.52% | +98.45% | 5.55TCr | |
| +0.14% | +2.35% | +13.08% | +109.47% | 4.76TCr | |
| -2.21% | -2.47% | +18.60% | +36.89% | 4.37TCr | |
| -2.30% | -10.40% | +167.61% | +776.79% | 3.73TCr | |
| +2.15% | +1.42% | +15.17% | +56.49% | 3.66TCr | |
| -2.32% | -2.24% | +75.52% | +52.70% | 3.22TCr | |
| +2.62% | +5.90% | -36.55% | +406.95% | 2.66TCr | |
| Average | -0.55% | -0.52% | +29.54% | +168.11% | 4TCr | |
| Weighted average by Cap. | -0.83% | +0.20% | +37.22% | +162.17% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 12.64L 11.46L 10.6L 10L 18.02L 12Cr 18.65L 1.27Cr 50.48L 6.37Cr 47.44L 46.44L 20Cr | 22.79L 20.65L 19.1L 17.24L 32.48L 21Cr 33.63L 2.29Cr 91L 11Cr 85.53L 83.72L 36Cr |
| Net income | -2.72Cr -2.46Cr -2.28Cr -2.06Cr -3.88Cr -256.48Cr -4.01Cr -27Cr -11Cr -137Cr -10Cr -9.99Cr -434.89Cr | -2.92Cr -2.64Cr -2.44Cr -2.2Cr -4.15Cr -274.88Cr -4.3Cr -29Cr -12Cr -146.83Cr -11Cr -11Cr -466.09Cr |
| Net Debt | -99.53L -90.19L -83.42L -75.27L -1.42Cr -94Cr -1.47Cr -10Cr -3.97Cr -50Cr -3.74Cr -3.66Cr -159.13Cr | -3.69Cr -3.35Cr -3.1Cr -2.79Cr -5.26Cr -348.24Cr -5.45Cr -37Cr -15Cr -186.02Cr -14Cr -14Cr -590.48Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | A$0.2500 | 0.00% | 62,653 |
| 12/26/12 | A$0.2500 | -9.09% | 3,30,038 |
| 11/26/11 | A$0.2750 | +1.85% | 5,38,934 |
| 10/26/10 | A$0.2700 | -10.00% | 2,31,920 |
| 09/26/09 | A$0.3000 | +13.21% | 64,059 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
Select your edition
All financial news and data tailored to specific country editions
